X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
INDRAPRASTHA MEDICAL CORP. LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

INDRAPRASTHA MEDICAL CORP. LTD.  (IRMED)


Here is the latest financial fact sheet of INDRAPRASTHA MEDICAL. For more details, see the INDRAPRASTHA MEDICAL quarterly results and INDRAPRASTHA MEDICAL share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
indraprastha medical - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 55.4       No. of shares m 91.67
    Mkt Cap Rs m 5,079       % ch % -1.0
    Vol '000 11.7       % ch week % -0.6
    P/E X 18.3       % ch 1-mth % 0.5
    P/CF X 8.0       % ch 12-mth % 7.4
    EPS (TTM) Rs 3.0       52 week H/L Rs 63.4/45.0
(As on Mar 24, 2017 (Close)) »  Best Performing health services Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-10
12
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs5453444241 
Low Rs2830313229 
Sales per share (Unadj.) Rs46.347.554.964.572.0 
Earnings per share (Unadj.) Rs3.43.42.93.13.9 
Diluted earnings per shareRs3.43.42.93.13.9 
Cash flow per share (Unadj.) Rs5.55.75.36.06.9 
Dividends per share (Unadj.) Rs1.601.601.601.601.80 
Adj. dividends per shareRs1.601.601.601.601.80 
Dividend yield (eoy) %3.93.94.34.35.1 
Book value per share (Unadj.) Rs14.816.317.418.720.4 
Adj. book value per shareRs14.816.317.418.720.4 
Shares outstanding (eoy) m91.6791.6791.6791.6791.67 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.90.90.70.60.5 
Avg P/E ratio x12.112.412.711.99.1 
P/CF ratio (eoy) x7.57.37.06.35.1 
Price / Book Value ratio x2.82.52.22.01.7 
Dividend payout %47.247.754.351.046.6 
Avg Mkt Cap Rs m3,7583,8043,4383,4283,222 
No. of employees `0002.93.02.93.23.1 
Total wages/salary Rs m8249851,1781,2661,418 
Avg. sales/employee Rs Th1,444.11,430.61,739.21,871.02,125.7 
Avg. wages/employee Rs Th280.5323.7407.3400.6456.6 
Avg. net profit/employee Rs Th105.7101.093.491.0114.1 
  INCOME DATA
Net Sales Rs m4,2444,3555,0305,9126,600 
Other income Rs m121269197169186 
Total revenues Rs m4,3654,6245,2266,0826,786 
Gross profit Rs m576434481631733 
Depreciation Rs m193216218259281 
Interest Rs m3944598696 
Profit before tax Rs m466443400455542 
Minority Interest Rs m00000 
Prior Period Items Rs m09000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m155145130167187 
Profit after tax Rs m311307270288354 
Gross profit margin %13.610.09.610.711.1 
Effective tax rate %33.332.832.536.834.6 
Net profit margin %7.37.15.44.95.4 
  BALANCE SHEET DATA
Current assets Rs m9079501,1941,3201,473 
Current liabilities Rs m1,3191,2821,7631,9621,920 
Net working cap to sales %-9.7-7.6-11.3-10.9-6.8 
Current ratio x0.70.70.70.70.8 
Inventory Days Days88777 
Debtors Days Days2427243236 
Net fixed assets Rs m2,0952,5982,7583,0032,947 
Share capital Rs m917917917917917 
"Free" reserves Rs m440577676793955 
Net worth Rs m1,3571,4931,5931,7101,871 
Long term debt Rs m44427279297258 
Total assets Rs m3,0023,5814,0204,3814,488 
Interest coverage x13.111.27.86.36.7 
Debt to equity ratio x00.30.20.20.1 
Sales to assets ratio x1.41.21.31.31.5 
Return on assets %11.69.88.28.510.0 
Return on equity %22.920.617.016.818.9 
Return on capital %36.025.824.527.029.9 
Exports to sales %00000 
Imports to sales %2.97.12.84.01.8 
Exports (fob) Rs m00000 
Imports (cif) Rs m122308140238116 
Fx inflow Rs m4015477367031,116 
Fx outflow Rs m141344197319218 
Net fx Rs m260203539384898 
  CASH FLOW
From Operations Rs m 730 334 555 669 581 
From Investments Rs m -361 -573 -280 -540 -218 
From Financial Activity Rs m -357 219 -268 -126 -361 
Net Cashflow Rs m 13 -20 7 3 2 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for indraprastha medical corp. ltd.

 Share Holding
Indian Promoters : 49.4%
Foreign collaborators : 1.6%
Indian inst/Mut Fund : 1.3%
FIIs : 0.5%
ADR/GDR : 0.0%
Free float : 47.2%
Shareholders : 38,169
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Sarita Vihar, Delhi - Mathura Road, New Delhi - 110 076
    E-MAIL: asinghal@apollohospitals.com     WEB: www.apollohospdelhi.com
    TELEPHONE: (011) 2692 5858     FAX: (011) 2682 5601
    SECTOR: HEALTH SERVICES     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, 44, 2nd Flr., Naraina Indl. Area, Phase I, New Delhi-28
    AUDITOR: S. C. Vasudeva & Co.
CHM: S. K. Srivastava COMP SEC: A. K. Singhal YEAR OF INC: 1900 BSE CODE: 532150 FV (Rs): 10 DIV YIELD (%): 3.2

More health services Company Fact Sheets:   PLETHICO PHARMAORCHID PHARMA LTDFULFORD INDIASTRIDES SHASUN LTDNATCO PHARMA


Today's Market

Global Financial Markets Remain Cautious(RoundUp)

Most of the global financial markets ended the week on a negative note. Major global markets were cautious over the week over concerns of the Trump administration's ability to push out reforms.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

More

TRACK INDRAPRASTHA MEDICAL

  • Track your investment in INDRAPRASTHA MEDICAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDRAPRASTHA MEDICAL

INDRAPRASTHA MEDICAL 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE INDRAPRASTHA MEDICAL WITH

MARKET STATS